Literature DB >> 11526967

A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive ratio schedule.

E Izzo1, C Orsini, G F Koob, L Pulvirenti.   

Abstract

A recently characterized class of compounds, dopamine partial agonists, have been suggested as potential therapeutic candidates for pharmacological intervention in psychostimulant addiction. These drugs bind to dopamine receptors with high affinity and low intrinsic activity and are thought to behave as functional antagonists in conditions of high dopaminergic tone, and as agonists in conditions of low receptor occupancy by dopamine. The aim of the present study was to characterize the effects of terguride, a partial dopamine agonist at the D2 receptor subtype, on intravenous self-administration of amphetamine in a progressive ratio schedule and to compare it with the effects produced by the dopamine D2 antagonist eticlopride and the dopamine D2 full agonist quinpirole. Terguride at the doses of 0.2 and 0.4 mg/kg i.p. significantly decreased the maximum number of responses delivered for a single injection of amphetamine ("breaking point"), an effect similar to that produced by the antagonist eticlopride (0.01-0.1 mg/kg s.c.). In contrast, administration of quinpirole (0.1-1 mg/kg s.c.) did not significantly modify the breaking point for amphetamine responding. Also, terguride dose-dependently increased responding for amphetamine self-administration on a continuous reinforcement schedule. These data further confirm the effects of terguride on psychostimulant self-administration and indicate that under these conditions partial dopamine agonists act as functional dopamine receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11526967     DOI: 10.1016/s0091-3057(01)00472-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  13 in total

1.  The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.

Authors:  Sanders A McDougall; Rita M Hernandez; Carmela M Reichel; Cristal M Farley
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

2.  Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats.

Authors:  Taco J De Vries; Judith R Homberg; Rob Binnekade; Halfdan Raasø; Anton N M Schoffelmeer
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

3.  Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys.

Authors:  Donna M Platt; Joshua S Rodefer; James K Rowlett; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2003-02-13       Impact factor: 4.530

4.  Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration.

Authors:  Sunmee Wee; Zhixia Wang; William L Woolverton; Luigi Pulvirenti; George F Koob
Journal:  Neuropsychopharmacology       Date:  2007-02-28       Impact factor: 7.853

Review 5.  Biological treatments for amfetamine dependence : recent progress.

Authors:  Kevin P Hill; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

6.  Dopamine enables in vivo synaptic plasticity associated with the addictive drug nicotine.

Authors:  Jianrong Tang; John A Dani
Journal:  Neuron       Date:  2009-09-10       Impact factor: 17.173

Review 7.  Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

Authors:  George F Koob; G Kenneth Lloyd; Barbara J Mason
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

Review 8.  Neurobiological substrates for the dark side of compulsivity in addiction.

Authors:  George F Koob
Journal:  Neuropharmacology       Date:  2008-08-07       Impact factor: 5.250

Review 9.  Histamine H₃ receptors, the complex interaction with dopamine and its implications for addiction.

Authors:  B A Ellenbroek
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

10.  Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.

Authors:  Phillip Oliver Coffin; Glenn-Milo Santos; Moupali Das; Deirdre M Santos; Shannon Huffaker; Tim Matheson; James Gasper; Eric Vittinghoff; Grant N Colfax
Journal:  Addiction       Date:  2013-01-03       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.